Oric Pharmaceuticals (ORIC)
(Delayed Data from NSDQ)
$9.33 USD
+0.50 (5.66%)
Updated May 1, 2024 04:00 PM ET
After-Market: $9.32 -0.01 (-0.11%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
ORIC 9.33 +0.50(5.66%)
Will ORIC be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for ORIC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ORIC
How Much Upside is Left in Oric Pharmaceuticals (ORIC)? Wall Street Analysts Think 39.3%
Recent Price Trend in Oric Pharmaceuticals, Inc. (ORIC) is Your Friend, Here's Why
ORIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Oric Pharmaceuticals, Inc. (ORIC) Is a Great Choice for 'Trend' Investors, Here's Why
Oric Pharmaceuticals, Inc. (ORIC) Upgraded to Buy: What Does It Mean for the Stock?
ORIC Rises on Team-Up With Pfizer for Multiple Myeloma Study
Other News for ORIC
Oric Pharmaceuticals participates in a conference call with JPMorgan
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
Oric Pharmaceuticals Breaks Below 200-Day Moving Average - Notable for ORIC
ORIC Pharmaceuticals Announces First Patients Dosed Across Three Expansion Cohorts in Phase 1b Trial of ORIC-114 in Patients with Mutated NSCLC
Oric doses first patient in dose escalation portion of ORIC-114 trial